The Léon Bérard Centre and GLEAMER sign a partnership to accelerate innovation in oncological imaging

Cécile Hourquet


GLEAMER, the European leader in artificial intelligence for radiology, and the Léon Bérard Centre, a Cancer Fight Centre (CLCC) in Lyon, France, have signed a strategic partnership to accelerate innovation in oncological imaging.

Since 2017, the Léon Bérard Centre (CLB) is involved in projects using artificial intelligence and computerized health databases to improve cancer care. This partnership with GLEAMER entirely fits into this dynamic. It will develop a solution for detecting and characterizing lesions in mammograms and tomosynthesis before turning to CT imaging, an essential examination in oncology for cancer staging and monitoring under treatment. “GLEAMER has recognized expertise in AI. Their R&D based in France will be able to rely on our Big Data and AI approach and the know-how of our teams to exploit databases, solve our professionals’ problems, and improve patient care,” says Pr. Jean-Yves Blay, director general of the CLB. This project will benefit from the ConSore tool, a search engine developed by the CLCC to accelerate clinical research. It will mobilize multidisciplinary teams from the CLB (IT and information systems management, radiologists) and GLEAMER (Data scientists, AI engineers).

The goal of the developed AI solutions will be to assist radiologists in detecting lesions earlier and to reduce interpretation times for frequently repeated exams in oncology. “In addition to scientific rigor, we share with GLEAMER a common vision of the contribution of AI for oncological imaging, which requires rare multidisciplinary expertise and analysis of enormous amounts of data,” says Dr. Pr Frank Pilleul, radiologist and head of the CLB’s imaging department.

Since its inception, GLEAMER has developed a set of innovative AI solutions in standard radiography, which are clinically adopted and whose performance, equal or superior to subspecialty experts, has been published in top-tier journals. Thanks to its latest funding round in June 2023, GLEAMER has the means to fulfill its ambitions: extend its AI Companion to modules dedicated to CT and breast imaging to cover 70% of the daily needs of radiologists tomorrow.

“This partnership will allow us to fulfill GLEAMER’s mission: to make AI the new standard of care in radiology to increase diagnostic accuracy, improve patient care, and optimize healthcare professional workflows. The expertise of the Léon Bérard Centre and access to aggregated oncology data will be key to developing and evaluating our solutions, to adapt them as closely as possible to user needs,” declares Christian Allouche, president and co-founder of GLEAMER.

Thanks to this partnership, GLEAMER and the CLB are joining forces to improve cancer diagnosis and care through AI, advancing medicine towards increasingly personalized paths.

About the Léon Bérard Centre

The Léon Bérard Centre is a member of the Unicancer network, which brings together 18 French cancer centers and an affiliated establishment. It is a regional, national, and international reference center for oncology. Located in Lyon, France’s second-largest metropolis, the CLB ensures a triple mission of care, research, and teaching, constantly wanting to increase the quality and accessibility of care for cancer patients. It offers on a single site all diagnostic examinations, treatments, and follow-ups of the person during and after the illness. It welcomes over 45,000 patients annually in hospitalization, consultation, or analysis, and 6,000 new tumors are diagnosed. The Centre employs over 2,200 employees, including 280 doctors, 600 researchers, and 800 caregivers. The continuum of care research is a strength of the Léon Bérard Centre. On its site, physicians and researchers work closely together to shorten the time between laboratory discoveries and their application to patients. Thus, more than 2,000 patients are included in one of the 300 clinical trials open to inclusion each year.

Related News

Gleamer raises €27 Million in series B to elevate the standard of care in radiology with AI

Gleamer is proud to announce a groundbreaking achievement: the successful completion of a Series B financing round, securing a remarkable €27 million in funding. This milestone marks a new chapter in Gleamer’s journey to revolutionize healthcare through cutting-edge technology. Supernova Invest leads the funding round, accompanied by co-leader Heal Capital

Gleamer and Imagerie Medicale du Parc Lyon (IMPL) announce a partnership to optimize patient care through AI

Gleamer and IMPL are pleased to announce their new partnership to optimize patient care in osteoarticular measurements through artificial intelligence. Gleamer has been supporting IMPL since 2021 with its BoneView algorithm, which assists in interpreting standard traumatic radiographs. This collaboration has led to a partnership to support

GLEAMER announces MDR-CE certification for Two new solutions.

Paris, France – March 3 2023 GLEAMER, a leading healthcare technology company, is proud to announce the MDR CE Certification of two new solutions: BoneView Measurements and BoneView Bone Age. These solutions are designed to optimize readers’ workflow and improve accuracy. The EU-MDR is a set of regulations established by